ArticleEuropean journal of nuclear medicine and molecular imaging2018
Diagnostic utility of FDG-PET in the differential diagnosis between different forms of primary progressive aphasia.
Article in European journal of nuclear medicine and molecular imaging, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 32 citations in OpenAlex.
- Validity of cingulate-precuneus-temporo-parietal hypometabolism for single-subject diagnosis of biomarker-proven atypical variants of Alzheimer's Disease.Journal of neurology · 2022Article
- Imaging Clinical Subtypes and Associated Brain Networks in Alzheimer's Disease.Brain sciences · 2022Review
- EANM procedure guidelines for brain PET imaging using [European journal of nuclear medicine and molecular imaging · 2022Article
- The use of systematic review evidence to support the development of guidelines for positron emission tomography: a cross-sectional survey.European radiology · 2021Article
- Anomaly detection for the individual analysis of brain PET images.Journal of medical imaging (Bellingham, Wash.) · 2021Article
- Neuroimaging in Frontotemporal Lobar Degeneration: Research and Clinical Utility.Advances in experimental medicine and biology · 2021Review
- Case Report: Semantic Variant of Primary Progressive Aphasia Associated With Anti-Glial Fibrillary Acid Protein Autoantibodies.Frontiers in immunology · 2021Article
- Genetic Algorithms for Optimized Diagnosis of Alzheimer's Disease and Frontotemporal Dementia Using Fluorodeoxyglucose Positron Emission Tomography Imaging.Frontiers in aging neuroscience · 2021Article
- Article
- An application of machine learning with feature selection to improve diagnosis and classification of neurodegenerative disorders.BMC bioinformatics · 2019Article
- Clinical and neuroimaging characteristics of clinically unclassifiable primary progressive aphasia.Brain and language · 2019Article
- Clinical utility of FDG-PET for the differential diagnosis among the main forms of dementia.European journal of nuclear medicine and molecular imaging · 2018Review
- Assessing FDG-PET diagnostic accuracy studies to develop recommendations for clinical use in dementia.European journal of nuclear medicine and molecular imaging · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 7 institutions in 8 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeA joint effort of the European Association of Nuclear Medicine (EANM) and the European Academy of Neurology (EAN) aims at clinical guidance for the use of FDG-PET in neurodegenerative diseases. This paper addresses the diagnostic utility of FDG-PET over clinical/neuropsychological assessment in the differentiation of the three forms of primary progressive aphasia (PPA).
methodsSeven panelists were appointed by the EANM and EAN and a literature search was performed by using harmonized PICO (Population, Intervention, Comparison, Outcome) question keywords. The studies were screened for eligibility, and data extracted to assess their methodological quality. Critical outcomes were accuracy indices in differentiating different PPA clinical forms. Subsequently Delphi rounds were held with the extracted data and quality assessment to reach a consensus based on both literature and expert opinion.
resultsCritical outcomes for this PICO were available in four of the examined papers. The level of formal evidence supporting clinical utility of FDG-PET in differentiating among PPA variants was considered as poor. However, the consensual recommendation was defined on Delphi round I, with six out of seven panelists supporting clinical use.
conclusionsQuantitative evidence demonstrating utility or lack thereof is still missing. Panelists decided consistently to provide interim support for clinical use based on the fact that a typical atrophy or metabolic pattern is needed for PPA according to the diagnostic criteria, and the synaptic failure detected by FDG-PET is an earlier phenomenon than atrophy. Also, a normal FDG-PET points to a non-neurodegenerative cause.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.